130 related articles for article (PubMed ID: 19669229)
1. Inhibition of the PI3K pathway suppresses hormonal secretion and limits growth in pheochromocytoma cells.
Adler JT; Hottinger DG; Kunnimalaiyaan M; Chen H
World J Surg; 2009 Nov; 33(11):2452-7. PubMed ID: 19669229
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of phosphatidylinositol 3-kinase/Akt signaling suppresses tumor cell proliferation and neuroendocrine marker expression in GI carcinoid tumors.
Pitt SC; Chen H; Kunnimalaiyaan M
Ann Surg Oncol; 2009 Oct; 16(10):2936-42. PubMed ID: 19588205
[TBL] [Abstract][Full Text] [Related]
3. Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells.
Pitt SC; Chen H; Kunnimalaiyaan M
J Am Coll Surg; 2009 Jul; 209(1):82-8. PubMed ID: 19651067
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002.
Kunnimalaiyaan M; Ndiaye M; Chen H
Surgery; 2006 Dec; 140(6):1009-14; discussion 1014-5. PubMed ID: 17188151
[TBL] [Abstract][Full Text] [Related]
5. Secretin receptor promotes the proliferation of endocrine tumor cells via the PI3K/AKT pathway.
Lee M; Waser B; Reubi JC; Pellegata NS
Mol Endocrinol; 2012 Aug; 26(8):1394-405. PubMed ID: 22692904
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells.
Adler JT; Hottinger DG; Kunnimalaiyaan M; Chen H
Surgery; 2008 Dec; 144(6):956-61; discussion 961-2. PubMed ID: 19041003
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy.
Krystal GW; Sulanke G; Litz J
Mol Cancer Ther; 2002 Sep; 1(11):913-22. PubMed ID: 12481412
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine.
Xie X; Tang B; Zhou J; Gao Q; Zhang P
Oncol Rep; 2013 Aug; 30(2):773-82. PubMed ID: 23743572
[TBL] [Abstract][Full Text] [Related]
9. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Liu Y; Chen X; Luo Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
[TBL] [Abstract][Full Text] [Related]
10. ZM336372, a Raf-1 activator, inhibits growth of pheochromocytoma cells.
Kappes A; Vaccaro A; Kunnimalaiyaan M; Chen H
J Surg Res; 2006 Jun; 133(1):42-5. PubMed ID: 16603190
[TBL] [Abstract][Full Text] [Related]
11. LY294002 inhibits the malignant phenotype of osteosarcoma cells by modulating the phosphatidylinositol 3‑kinase/Akt/fatty acid synthase signaling pathway in vitro.
Zhou Y; Zhu LB; Peng AF; Wang TF; Long XH; Gao S; Zhou RP; Liu ZL
Mol Med Rep; 2015 Feb; 11(2):1352-7. PubMed ID: 25351625
[TBL] [Abstract][Full Text] [Related]
12. LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway.
Xu R; Zhang Y; Li A; Ma Y; Cai W; Song L; Xie Y; Zhou S; Cao W; Tang X
Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33982772
[TBL] [Abstract][Full Text] [Related]
13. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
Li C; Liu VW; Chan DW; Yao KM; Ngan HY
Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
[TBL] [Abstract][Full Text] [Related]
14. The Role of the LY294002 - A Non-Selective Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) Pathway- in Cell Survival and Proliferation in Cell Line SCC-25.
Duarte A; Silveira GG; Soave DF; Costa JPO; Silva AR
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3377-3383. PubMed ID: 31759362
[TBL] [Abstract][Full Text] [Related]
15. Combinatorial therapy with adenoviral-mediated PTEN and a PI3K inhibitor suppresses malignant glioma cell growth in vitro and in vivo by regulating the PI3K/AKT signaling pathway.
Nan Y; Guo L; Song Y; Wang L; Yu K; Huang Q; Zhong Y
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1477-1487. PubMed ID: 28401302
[TBL] [Abstract][Full Text] [Related]
16. LY294002 enhances boswellic acid-induced apoptosis in colon cancer cells.
Liu JJ; Duan RD
Anticancer Res; 2009 Aug; 29(8):2987-91. PubMed ID: 19661305
[TBL] [Abstract][Full Text] [Related]
17. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
Lee HY; Oh SH; Suh YA; Baek JH; Papadimitrakopoulou V; Huang S; Hong WK
Clin Cancer Res; 2005 Aug; 11(16):6065-74. PubMed ID: 16115952
[TBL] [Abstract][Full Text] [Related]
18. [Effects of PI3K/Akt/NF-κB signal pathway on FSH facilitation on cell proliferation and invasion by human epithelial ovarian cancer].
Xu CL; Lu XL; Yan XN; Wang HL; Chen SQ
Zhonghua Fu Chan Ke Za Zhi; 2012 Feb; 47(2):134-8. PubMed ID: 22455747
[TBL] [Abstract][Full Text] [Related]
19. Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells.
Wu D; Tao J; Xu B; Qing W; Li P; Lu Q; Zhang W
Urol Int; 2011; 87(1):105-13. PubMed ID: 21597260
[TBL] [Abstract][Full Text] [Related]
20. [Telomerase activity,PI3K/AKT signaling pathway and cellular biological behavior in HeLa cell line].
Yu XX; Shi YA; Zhang LH; Wang YS; Wu S
Zhonghua Bing Li Xue Za Zhi; 2008 May; 37(5):323-7. PubMed ID: 18956651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
